Roche’s acquired GLP-1/GIP normalises blood sugar in Phase II trial

Phase 2positivePositive

AI Analysis

Summary

Roche announced positive Phase II trial results for an acquired GLP-1/GIP agonist that normalized blood sugar in patients with obesity and type 2 diabetes.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

normalized blood sugar

Importance:6/10

Sentiment:

0.60

GLP-1GIPobesitytype 2 diabetesPhase 2acquisition

Related Companies

$RHHBY

Read the original article

Published by Clinical Trials Arena on September 23, 2026 10:10 AM

Read Original